Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Blastic Plasmacytoid Dendritic Cell Neoplasm in the Dual CD123-targeted Therapy Era: A Clinical Decision Review of Treatment Selection, Sequencing, CNS Management, and Transplant Integration.","authors":"Xichang Fei, Haimin Chen, Ying Zhang, Fan Zhou","doi":"10.1016/j.clml.2026.09.005","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.005","url":null,"abstract":"<p><p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) has entered a dual CD123-targeted therapy era following the availability of tagraxofusp and the 2026 approval of pivekimab sunirine-pvzy. This development creates a new clinical problem: treatment can no longer be selected solely by distinguishing targeted therapy from conventional chemotherapy; clinicians must choose between mechanistically distinct CD123 platforms while integrating central nervous system (CNS) management, transplantation, comorbidity, organ function, and prior treatment. This narrative review reframes BPDCN around those decisions. It summarizes the minimum diagnostic and staging information needed before therapy; compares tagraxofusp and pivekimab using response, survival, follow-up, and transplant-bridging data; and proposes scenario-based approaches for newly diagnosed, older or frail, transplant-eligible, and relapsed or refractory patients. Tagraxofusp has the longest disease-specific experience and a defined role as remission induction and a bridge to hematopoietic cell transplantation, but capillary leak syndrome requires stringent selection and cycle-1 monitoring. Pivekimab offers a distinct antibody-drug conjugate platform with once-every-3-week dosing and activity in both treatment-naive and relapsed disease, but hepatotoxicity, including hepatic veno-occlusive disease, is a central limitation. Neither agent has established CNS-protective activity. Baseline cerebrospinal fluid assessment and routine prophylactic intrathecal chemotherapy for CSF-negative patients should therefore be distinguished from intensified therapeutic intrathecal treatment for documented CNS involvement. Early donor search, multidimensional response evaluation, and trial enrollment remain integral. The proposed algorithm is evidence-informed rather than guideline-mandated and highlights where prospective studies are most urgently needed.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma.","authors":"Aurore Perrot, Salomon Manier, Cyrille Hulin, Hélène Demarquette, Arthur Bobin, Laurent Frenzel, Lionel Karlin, Olivier Decaux, Mohamad Mohty, Bertrand Arnulf, Jérôme Lambert, Jill Corre, Thierry Facon, Philippe Moreau, Cyrille Touzeau, Xavier Leleu","doi":"10.1016/j.clml.2026.09.002","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.002","url":null,"abstract":"<p><p>The treatment landscape of newly diagnosed multiple myeloma (NDMM) has changed considerably over the past 5 years. Anti-CD38-VRd quadruplets are now the standard of care for transplant-eligible patients and an important option for transplant-ineligible patients. This review presents unified, evidence-based first-line treatment recommendations from the Intergroupe Francophone du Myélome (IFM), covering transplant-eligible and transplant-ineligible NDMM within a single framework and common methodology. In transplant-eligible patients, daratumumab-VRd and isatuximab-VRd, informed respectively by the PERSEUS and GMMG-HD7 trials, are now the reference induction regimens, followed by autologous stem cell transplantation, optional consolidation, and daratumumab-lenalidomide maintenance. In transplant-ineligible patients, daratumumab-lenalidomide-dexamethasone (DRd), informed by the MAIA trial, remains the treatment backbone: in fit patients, adding bortezomib (isatuximab-VRd or daratumumab-VRd, informed by IMROZ, CEPHEUS, and BENEFIT) could further improve outcomes, while frail patients receive the same backbone without dexamethasone (DR), informed by IFM2017-03. Mathematical modeling projects a median progression-free survival of approximately 205 months with daratumumab-VRd in transplant-eligible patients (PERSEUS model) and approximately 100 months in transplant-ineligible/transplant-deferred patients (CEPHEUS model), approaching for the first time a normal life expectancy for a substantial subset of patients and supporting the emerging concept of functional cure. We discuss the role of measurable residual disease and NGS-based high-risk myeloma definition across both populations, and position these recommendations relative to the 2025 EHA-EMN evidence-based guidelines. Finally, we summarize ongoing trials investigating T-cell-redirecting immunotherapies (CAR-T cells and bispecific antibodies) as replacements for, or additions to, ASCT and maintenance therapy, which may further reshape the first-line treatment paradigm in the coming years.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive Multifocal Leukoencephalopathy Following Bispecific Antibody Therapy in Multiple Myeloma: A Case Series.","authors":"Tyler B Sandahl, Morie Gertz, Wilson I Gonsalves, Vy Huynh, David Dingli","doi":"10.1016/j.clml.2026.09.001","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.001","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.","authors":"Gurdeep Parmar, Marcelo Capra, Vania Hungria, Fernanda Salles Seguro, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Ivan Špička, Jiří Minařík, Herlander Marques, Ludĕk Pour, Jana Mihályová, Junichiro Yuda, Kazutaka Sunami, Graça Esteves, Cynthia Chmielewski, Christine Soufflet, Disa Yu, Erin Comerford, Florence Suzan, Paul Cordero, Rick Zhang, Hang Quach","doi":"10.1016/j.clml.2026.08.019","DOIUrl":"https://doi.org/10.1016/j.clml.2026.08.019","url":null,"abstract":"<p><strong>Background: </strong>The phase 2 IZALCO study (NCT05704049) demonstrated comparable efficacy, safety, and pharmacokinetics for subcutaneous (SC) isatuximab administered via an on-body injector (Isa SC OBI) versus manual injection in combination with carfilzomib-dexamethasone in relapsed/refractory multiple myeloma.</p><p><strong>Patients and methods: </strong>We evaluated patient-reported outcomes (PROs) in 74 adults and experiences of 19 healthcare providers (HCPs) from IZALCO. In part 1, Isa was given via manual injection. In part 2, patients were randomly assigned to manual injection or Isa SC OBI in cycle (C)1-3 and crossed over to the other method for C4-6. From C7, patients could select either method. Patient preference of delivery method at C6 Day (D)15 was a key secondary endpoint (n = 47). PROs and HCP experience were assessed using the Patient Expectations Questionnaire, Patient Experience and Satisfaction Questionnaire, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and HCP questionnaire.</p><p><strong>Results: </strong>In part 2, at C6D15, after experiencing both methods, 74.5% (35/47) of patients preferred Isa SC OBI over manual injection, with comfort, convenience, and reduced injection-site pain being the main reasons for preference. Fewer patients reported discomfort, pain, and side effects with Isa SC OBI versus manual injection at most time points. Most patients (90.4%, 47/52) opted for Isa SC OBI from C7 onward. Mean EORTC QLQ-C30 global health status/QoL score was maintained over time. Of 19 HCPs, 78.9% (15/19) preferred Isa SC OBI versus manual injection.</p><p><strong>Conclusion: </strong>These findings support Isa SC OBI as the preferred administration method for patients and HCPs.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149058708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-41 Mitigating Cilta-cel-Associated Delayed Neurotoxicity in Patients with High Lymphocyte Expansion: A Prospective Observational Comparative Study of Prophylactic Cyclophosphamide","authors":"Christoph Schaefers,&nbsp;Melinda Tan,&nbsp;Kenneth Lim,&nbsp;Darin D. Carabenciov,&nbsp;Katharine E. Dooley,&nbsp;Nadine H. Abdallah,&nbsp;Saurabh Chhabra,&nbsp;Ricardo Parrondo,&nbsp;Morie Gertz,&nbsp;Taxiarchis Kourelis,&nbsp;Rahma Warsame,&nbsp;Joselle Cook,&nbsp;Moritz Binder,&nbsp;De Menezes Silva Corraes Andre,&nbsp;Malvika Gupta,&nbsp;Udit Yadav,&nbsp;Leif Bergsagel,&nbsp;Julia Erin Wiedmeier-Nutor,&nbsp;Saurabh Zanwar,&nbsp;Rafael Fonseca,&nbsp;Yi Lin","doi":"10.1016/S2152-2650(26)03342-2","DOIUrl":"10.1016/S2152-2650(26)03342-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 ","pages":"Page S27"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PA-008 A Phase 1/2, Open-Label, Platform Study to Evaluate the Safety and Efficacy of Etentamig Monotherapy or Combination Therapy in Patients with Multiple Myeloma","authors":"Karthik Nath,&nbsp;Hila Magen,&nbsp;Peter Forsberg,&nbsp;Ariel Grajales-Cruz,&nbsp;John McKay,&nbsp;Darren Pan,&nbsp;Matthew Pianko,&nbsp;Fredrik Schjesvold,&nbsp;Faisal Rahman,&nbsp;Jovian Yu,&nbsp;Kojo Osei-Bonsu,&nbsp;Matthew Bentley,&nbsp;Sunny He,&nbsp;Hillary M. Peltier,&nbsp;Ly Pham,&nbsp;Jordan Morrissey,&nbsp;Eben Lichtman","doi":"10.1016/S2152-2650(26)03379-3","DOIUrl":"10.1016/S2152-2650(26)03379-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 ","pages":"Pages S50-S51"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PA-006 A New Prognostic Model Based on Age and LDH Which is More Suitable for Prognostic Stratification of MM with Extramedullary Bone Involvement","authors":"Feilong Zhu,&nbsp;Juan Li","doi":"10.1016/S2152-2650(26)03377-X","DOIUrl":"10.1016/S2152-2650(26)03377-X","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 ","pages":"Pages S49-S50"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-26 Feasibility of MRD-adapted Deferral of Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: Clinical and Translational Results from the Phase II MILESTONE Study","authors":"Susan Bal,&nbsp;Esther Zumaquero,&nbsp;Gayathri Ravi,&nbsp;Kelly Godby,&nbsp;Smith Giri,&nbsp;Caitlin Hagedorn,&nbsp;Laura Joiner,&nbsp;Alexander Rosenberg,&nbsp;Davide Botta,&nbsp;Betty Mousseau,&nbsp;Fen Zhou,&nbsp;Suki Chen,&nbsp;Amna Siddiqui,&nbsp;Frances Lund,&nbsp;Luciano J. Costa","doi":"10.1016/S2152-2650(26)03327-6","DOIUrl":"10.1016/S2152-2650(26)03327-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 ","pages":"Pages S17-S18"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-27 Fifteen-Month Follow-Up from a Pivotal Trial of GR1803 in Patients with Relapsed/Refractory Multiple Myeloma","authors":"Jie Jin,&nbsp;Wenming Chen,&nbsp;Weijun Fu,&nbsp;Min Yang,&nbsp;Ying Tian,&nbsp;Hua Jiang,&nbsp;Jie Ma,&nbsp;Baijun Fang,&nbsp;Yanjuan He,&nbsp;Pengcheng He,&nbsp;Wei Yang,&nbsp;Chengcheng Fu,&nbsp;Yingyu Nan,&nbsp;Jun Wang,&nbsp;Chunrui Li,&nbsp;Bing Chen,&nbsp;Jian Hou,&nbsp;Hongyu Zhang,&nbsp;Wei Wang,&nbsp;Ying Lu,&nbsp;Huili Cai","doi":"10.1016/S2152-2650(26)03328-8","DOIUrl":"10.1016/S2152-2650(26)03328-8","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 ","pages":"Page S18"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA-48 Outcomes of Anti-BCMA CAR-T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and CNS Involvement Based on a Multicenter Real-World Study With Extended Follow-Up","authors":"Sven Neubert,&nbsp;Markus Maulhardt,&nbsp;Inna Shaforostova,&nbsp;Stephan Bohl,&nbsp;Raphael Teipel,&nbsp;Natalie Schub,&nbsp;Anca-Maria Albici,&nbsp;Keven Hoerster,&nbsp;Amelie Boquoi,&nbsp;Snjezana Janjetovic,&nbsp;Elisa Kim Alves Carpinteiro,&nbsp;Tim Richardson,&nbsp;Thomas Pabst,&nbsp;Judith S. Hecker,&nbsp;Kim Agnes Munoz Alvarez,&nbsp;Justin Hasenkamp,&nbsp;Gerald Wulf,&nbsp;Georg Lenz,&nbsp;Hermann Einsele,&nbsp;Leo Rasche,&nbsp;Johannes Waldschmidt","doi":"10.1016/S2152-2650(26)03349-5","DOIUrl":"10.1016/S2152-2650(26)03349-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 ","pages":"Pages S31-S32"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}